PDCD1 and nonpapillary renal cell carcinoma: ICI‐based therapies targeting the programmed cell death protein 1 (PD1)‐programmed cell death ligand 1 (PD‐L1) axis (e.g. pembroluzimab and nivolumab) are now approved as first‐line therapies for metastatic CCRCC [5, 17].